École de Santé Publique de l'Université de Montréal (ESPUM), Canada; McGill International TB Center, Montreal, Canada; Centre de Recherche en Santé Publique, Université de Montréal (CReSP), Canada.
Azhee Akinrin Consulting, Nigeria.
Healthc (Amst). 2021 Jun;9(2):100487. doi: 10.1016/j.hjdsi.2020.100487. Epub 2020 Oct 22.
The coronavirus disease 2019 (COVID-19) has emerged as a serious threat to global public health, demanding urgent action and causing unprecedented worldwide change in a short space of time. This disease has devastated economies, infringed on individual freedoms, and taken an unprecedented toll on healthcare systems worldwide. As of 1 April 2020, over a million cases of COVID-19 have been reported in 204 countries and territories, resulting in more than 51,000 deaths. Yet, against the backdrop of the COVID-19 pandemic, lies an older, insidious disease with a much greater mortality. Tuberculosis (TB) is the leading cause of death by a single infectious agent and remains a potent threat to millions of people around the world. We discuss the differences between the two pandemics at present, consider the potential impact of COVID-19 on TB case management, and explore the opportunities that the COVID-19 response presents for advancing TB prevention and control now and in future.
2019 年冠状病毒病(COVID-19)的爆发对全球公共卫生构成了严重威胁,需要采取紧急行动,并在短时间内导致全球前所未有的变化。这种疾病破坏了经济,侵犯了个人自由,并对全球的医疗体系造成了前所未有的冲击。截至 2020 年 4 月 1 日,204 个国家和地区报告了超过 100 万例 COVID-19 病例,导致超过 51,000 人死亡。然而,在 COVID-19 大流行的背景下,存在着一种更为古老、阴险的疾病,其死亡率更高。结核病(TB)是单一传染病原体导致死亡的主要原因,仍然是全球数百万人的严重威胁。我们讨论了目前这两种大流行之间的差异,考虑了 COVID-19 对结核病病例管理的潜在影响,并探讨了 COVID-19 应对措施为当前和未来推进结核病预防和控制带来的机遇。